Associated Genetic Biomarkers
Werner syndrome, RecQ helicase-like (WRN) is a gene that encodes a protein that functions as a DNA helicase. Missense mutations, silent mutations, nonsense mutations, in-frame deletions, and frameshift deletions are observed in cancers such as peritoneal cancer, colon cancer, and stomach cancer.
WRN is altered in 3.21% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, melanoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations .
The most common alterations in WRN are WRN Mutation (2.86%), WRN Loss (0.30%), WRN S1128fs (0.09%), WRN T172P (0.06%), and WRN Amplification (0.04%) .
WRN status serves as an inclusion eligibility criteria in 5 clinical trials, of which 4 are open and 1 is closed. Of the trials that contain WRN status as an inclusion criterion, 1 is phase 1 (1 open) and 4 are phase 2 (3 open).
Trials with WRN status in the inclusion eligibility criteria most commonly target malignant solid tumor, breast carcinoma, small cell lung carcinoma, and urothelial carcinoma .
The most frequent alterations to serve as inclusion eligibility criteria are WRN Mutation and WRN Mutation (germline) .
Niraparib, olaparib, carboplatin, cisplatin, and gemcitabine are the most frequent therapies in trials with WRN as an inclusion criteria .
Significance of WRN in Diseases
Malignant Solid Tumor +
WRN is altered in 3.36% of malignant solid tumor patients .
WRN is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain WRN status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) .
Urothelial Carcinoma +
Breast Carcinoma +
Uveal Melanoma +
Small Cell Lung Carcinoma +
WRN is altered in 1.54% of small cell lung carcinoma patients .
WRN is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains WRN status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) .
Clear Cell Renal Cell Carcinoma +
WRN is altered in 1.1% of clear cell renal cell carcinoma patients .
WRN is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains WRN status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.